Analyst consensus rating
Sunshine Biopharma Inc. Analyst Rating: none
SBFM is rated none by 1 analysts with a $56.00 target. As of 2026-08-15.
Direct answer
Sunshine Biopharma Inc.'s consensus rating is none.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $56.00.
Forecast evidence checked August 15, 2026.
Get free Sunshine Biopharma Inc. email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.15
- Average price target
- $56.00
- High price target
- $56.00
- Low price target
- $56.00
- Low target gap
- +4,769.6%
- Target upside
- +4,769.6%
- High target gap
- +4,769.6%
- Target range width
- 0%
- Consensus rating
- none
- Analysts
- 1
- Evidence date
- August 15, 2026
- Valid through
- August 22, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Sunshine Biopharma Inc.?
Sunshine Biopharma Inc. has a verified none consensus. The same dataset has an average price target of $56.00.
How far are Sunshine Biopharma Inc.'s low and high targets from the recorded price?
The low target implies +4,769.6%, while the high target implies +4,769.6%.
How many analysts are included in Sunshine Biopharma Inc.'s consensus?
The verified consensus includes 1 analysts.
How is Sunshine Biopharma Inc.'s target upside or downside calculated?
The average target of $56.00 is divided by the recorded price of $1.15, then one is subtracted to produce +4,769.6%. This does not guarantee a future return.
When was Sunshine Biopharma Inc.'s analyst forecast verified?
The data was verified on 2026-08-15. The dataset is valid through 2026-08-22.